Prediction of prognostic and immune therapy response in lung adenocarcinoma based on MHC-I-related genes

References

• Succony L, Rassl DM, Barker AP, et al. Adenocarcinoma spectrum lesions of the lung: detection, pathology and treatment strategies. Cancer Treat Rev. 2021;99:102237. doi: 10.1016/j.ctrv.2021.102237.
   PubMed Web of Science ®Google Scholar
• Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943–953. doi: 10.2147/CMAR.S187317.
   PubMed Web of Science ®Google Scholar
• Yu W, Liu F, Lei Q, et al. Identification of key pathways and genes related to immunotherapy resistance of LUAD based on WGCNA analysis. Front Oncol. 2021;11:814014. doi: 10.3389/fonc.2021.814014.
   PubMed Web of Science ®Google Scholar
• Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 inhibitor (sintilimab) in NSCLC. J Thorac Oncol. 2020;15(5):816–826. doi: 10.1016/j.jtho.2020.01.017.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723. doi: 10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 2018;24(1):47–53. doi: 10.1097/PPO.0000000000000303.
   PubMed Web of Science ®Google Scholar
• Gemelli M, Noonan DM, Carlini V, et al. Overcoming resistance to checkpoint inhibitors: natural killer cells in Non-Small cell lung cancer. Front Oncol. 2022;12:886440. doi: 10.3389/fonc.2022.886440.
   PubMedGoogle Scholar
• Song P, Li W, Guo L, et al. Identification and validation of a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma by integrated analysis of Single-Cell and bulk RNA-Sequencing. Front Immunol. 2022;13:850745. doi: 10.3389/fimmu.2022.850745.
   PubMed Web of Science ®Google Scholar
• Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12:636568. doi: 10.3389/fimmu.2021.636568.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581(7806):100–105. doi: 10.1038/s41586-020-2229-5.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Gusenleitner D, Jackson DG, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10(450):eaar3342 doi: 10.1126/scitranslmed.aar3342.
   PubMed Web of Science ®Google Scholar
• Gu SS, Zhang W, Wang X, et al. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov. 2021;11(6):1524–1541. doi: 10.1158/2159-8290.CD-20-0812.
   PubMed Web of Science ®Google Scholar
• Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). 2020;12(7):1760. doi: 10.3390/cancers12071760.
   PubMed Web of Science ®Google Scholar
• Yang S, Tang D, Zhao YC, et al. Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival. Cancer Immunol Immunother. 2021;70(10):2819–2833. doi: 10.1007/s00262-021-02877-9.
   PubMed Web of Science ®Google Scholar
• Tu J, Xu H, Ma L, et al. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics. 2022;12(2):747–766. doi: 10.7150/thno.65828.
   PubMed Web of Science ®Google Scholar
• Mi K, Chen F, Qian Z, et al. Characterizing heterogeneity of non-small cell lung tumour microenvironment to identify signature prognostic genes. J Cell Mol Med. 2020;24(24):14608–14618. doi: 10.1111/jcmm.16092.
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Soft. 2010;33(1):1–22. doi: 10.18637/jss.v033.i01.
   PubMed Web of Science ®Google Scholar
• Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381–5397. doi: 10.1002/sim.5958.
   PubMed Web of Science ®Google Scholar
• Huang C, Liu Z, Xiao L, et al. Clinical significance of serum CA125, CA19-9, CA72-4, and fibrinogen-to-Lymphocyte ratio in gastric cancer with peritoneal dissemination. Front Oncol. 2019;9:1159. doi: 10.3389/fonc.2019.01159.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi: 10.1038/s41591-018-0136-1.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi: 10.1016/j.celrep.2016.12.019.
   PubMed Web of Science ®Google Scholar
• Skidmore ZL, Wagner AH, Lesurf R, et al. GenVisR: genomic visualizations in R. Bioinformatics. 2016;32(19):3012–3014. doi: 10.1093/bioinformatics/btw325.
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi: 10.1101/gr.239244.118.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang J, Xu FP, et al. Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma. J Thorac Oncol. 2019;14(11):1912–1923. doi: 10.1016/j.jtho.2019.07.031.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang Z, Li L, et al. An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles. Commun Biol. 2020;3(1):505. doi: 10.1038/s42003-020-01230-7.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140. doi: 10.1093/bioinformatics/btp616.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi: 10.1089/omi.2011.0118.
   PubMed Web of Science ®Google Scholar
• Lamb J. The connectivity map: a new tool for biomedical research. Nat Rev Cancer. 2007;7(1):54–60. doi: 10.1038/nrc2044.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Narayan R, Corsello SM, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437–1452 e17. doi: 10.1016/j.cell.2017.10.049.
   PubMed Web of Science ®Google Scholar
• Enache OM, Lahr DL, Natoli TE, et al. The GCTx format and cmap{Py, R, M, J} packages: resources for optimized storage and integrated traversal of annotated dense matrices. Bioinformatics. 2019;35(8):1427–1429. doi: 10.1093/bioinformatics/bty784.
   PubMed Web of Science ®Google Scholar
• Mostafa-Hedeab G, Al-Kuraishy HM, Al-Gareeb AI, et al. A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19. Inflammopharmacology. 2022;30(3):799–809. doi: 10.1007/s10787-022-00993-1.
   PubMed Web of Science ®Google Scholar
• Xu F, Huang X, Li Y, et al. m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD. Mol Ther Nucleic Acids. 2021;24:780–791. doi: 10.1016/j.omtn.2021.04.003.
   PubMedGoogle Scholar
• Ren J, Li N, Pei S, et al. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-gamma-stimulated antitumor immunity. J Clin Invest. 2022;132(8):132.
   Web of Science ®Google Scholar
• Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298–312. doi: 10.1038/s41568-021-00339-z.
   PubMed Web of Science ®Google Scholar
• Jongsma MLM, Guarda G, Spaapen RM. The regulatory network behind MHC class I expression. Mol Immunol. 2019;113:16–21. doi: 10.1016/j.molimm.2017.12.005.
   PubMed Web of Science ®Google Scholar
• Mantel I, Sadiq BA, Blander JM. Spotlight on TAP and its vital role in antigen presentation and cross-presentation. Mol Immunol. 2022;142:105–119. doi: 10.1016/j.molimm.2021.12.013.
   PubMed Web of Science ®Google Scholar
• Liu C, Chen Z, Ding X, et al. Ubiquitin-specific protease 35 (USP35) mediates cisplatin-induced apoptosis by stabilizing BIRC3 in non-small cell lung cancer. Lab Invest. 2022;102(5):524–533. doi: 10.1038/s41374-021-00725-z.
   PubMed Web of Science ®Google Scholar
• Xiao R, Shi L, Yang T, et al. Identification of RRAS gene related to nasopharyngeal carcinoma based on pathway and network-based analyses. Transl Cancer Res. 2019;8(2):664–675. doi: 10.21037/tcr.2019.04.04.
   PubMed Web of Science ®Google Scholar
• Alkhateeb A, Rezaeian I, Singireddy S, et al. Transcriptomics signature from Next-Generation sequencing data reveals new transcriptomic biomarkers related to prostate cancer. Cancer Inform. 2019;18:1176935119835522. doi: 10.1177/1176935119835522.
   Web of Science ®Google Scholar
• Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255. doi: 10.1186/s13046-019-1259-z.
   PubMed Web of Science ®Google Scholar
• Gao J, Wu M, Wang F, et al. CD74, a novel predictor for bronchopulmonary dysplasia in preterm infants. Medicine (Baltimore). 2020;99(48):e23477. doi: 10.1097/MD.0000000000023477.
   PubMed Web of Science ®Google Scholar
• Ishina IA, Zakharova MY, Kurbatskaia IN, et al. MHC class II presentation in autoimmunity. Cells. 2023;12(2):314. doi: 10.3390/cells12020314.
   PubMed Web of Science ®Google Scholar
• Fang H, Ma W, Guo X, et al. PTPN6 promotes chemosensitivity of colorectal cancer cells via inhibiting the SP1/MAPK signalling pathway. Cell Biochem Funct. 2021;39(3):392–400. doi: 10.1002/cbf.3604.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25(15):4592–4602. doi: 10.1158/1078-0432.CCR-18-1538.
   PubMed Web of Science ®Google Scholar
• Garrido F, Aptsiauri N. Cancer immune escape: MHC expression in primary tumours versus metastases. Immunology. 2019;158(4):255–266. doi: 10.1111/imm.13114.
   PubMed Web of Science ®Google Scholar
• Landre T, Justeau G, Assie JB, et al. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2022;71(3):719–726. doi: 10.1007/s00262-021-03031-1.
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, et al. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–173. doi: 10.1016/j.ccell.2020.10.001.
   PubMed Web of Science ®Google Scholar
• Chen T, Zhang X, Ding X, et al. Ryanodine receptor 2 promotes colorectal cancer metastasis by the ROS/BACH1 axis. Mol Oncol. 2023;17(4):695–709. doi: 10.1002/1878-0261.13350.
   PubMed Web of Science ®Google Scholar
• Saad HM, Tourky GF, Al-Kuraishy HM, et al. The potential role of MUC16 (CA125) biomarker in lung cancer: a magic biomarker but with adversity. Diagnostics (Basel). 2022;12(12):2985. doi: 10.3390/diagnostics12122985.
   PubMedGoogle Scholar
• Qi G, Li L. LncRNA TTN-AS1 promotes progression of non-small cell lung cancer via regulating miR-491-5p/ZNF503 axis. Onco Targets Ther. 2020;13:6361–6371. doi: 10.2147/OTT.S238890.
   PubMedGoogle Scholar
• Zheng QX, Wang J, Gu XY, et al. TTN-AS1 as a potential diagnostic and prognostic biomarker for multiple cancers. Biomed Pharmacother. 2021;135:111169. doi: 10.1016/j.biopha.2020.111169.
   PubMed Web of Science ®Google Scholar
• Zhou X, Hao Q, Lu H. Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol. 2019;11(4):293–305. doi: 10.1093/jmcb/mjy072.
   PubMed Web of Science ®Google Scholar
• Chen Z, Huang Y, Hu Z, et al. Landscape and dynamics of single tumor and immune cells in early and advanced-stage lung adenocarcinoma. Clin Transl Med. 2021;11:e350.
   PubMed Web of Science ®Google Scholar
• Ma L, Hernandez MO, Zhao Y, et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell. 2019;36(4):418–430 e6. doi: 10.1016/j.ccell.2019.08.007.
   PubMed Web of Science ®Google Scholar
• Dentro SC, Leshchiner I, Haase K, et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell. 2021;184(8):2239–2254 e39. doi: 10.1016/j.cell.2021.03.009.
   PubMed Web of Science ®Google Scholar
• Avitabile M, Bonfiglio F, Aievola V, et al. Single-cell transcriptomics of neuroblastoma identifies chemoresistance-associated genes and pathways. Comput Struct Biotechnol J. 2022;20:4437–4445. doi: 10.1016/j.csbj.2022.08.031.
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhu B, Hutchinson A, et al. Clinical implications of inter- and intratumor heterogeneity of immune cell markers in lung cancer. J Natl Cancer Inst. 2022;114(2):280–289. doi: 10.1093/jnci/djab157.
   PubMedGoogle Scholar
• Lee JG, Shim S, Kim MJ, et al. Pentoxifylline regulates plasminogen activator inhibitor-1 expression and protein kinase a phosphorylation in Radiation-Induced lung fibrosis. Biomed Res Int. 2017;2017:1279280. doi: 10.1155/2017/1279280.
   PubMed Web of Science ®Google Scholar
• Thomas JP, Loke YK, Alexandre L. Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials. Eur J Clin Pharmacol. 2020;76(12):1639–1651. doi: 10.1007/s00228-020-02967-0.
   PubMed Web of Science ®Google Scholar